By: Benzinga
UPDATE: Jefferies Initiates Anthera Pharmaceuticals at Buy on Blisibimod Outlook
Jefferies initiated coverage on Anthera Pharmaceuticals (NASDAQ: ANTH ) with a Buy rating and a $2.00 price target. Jefferies noted, "Despite conducting a well randomized Phase II trial, and improving its Phase III odds by identifying a more targeted lupus patient population, Anthera trades at a ~$50 million EV (v
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here